Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bromfenac ophthalmic - InSite Vision

Next Previous
Drug Profile

Bromfenac ophthalmic - InSite Vision

Alternative Names: Bromfenac ophthalmic 0.075%; BromSite; ISV-101; ISV-303

Latest Information Update: 08 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSite Vision; Sun Pharmaceutical Industries
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • No development reported Dry eyes; Retinal oedema

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-I/II for Dry eyes in USA (Ophthalmic)
  • 28 Aug 2018 No recent reports of development identified for research development in Retinal oedema(Prevention) in USA (Ophthalmic, Drops)
  • 08 Sep 2017 InSite Vision plans a phase II trial of bromfenac ophthalmic for Dry eye disease in 2018 (NCT01478555)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top